Taysha Gene Therapies, Inc.
TSHA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $2 | $2 | $2 |
| % Growth | -100% | -13.7% | 13.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $2 | $2 | $2 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $25 | $20 | $16 | $15 |
| G&A Expenses | $8 | $9 | $8 | $7 |
| SG&A Expenses | $8 | $9 | $8 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $34 | $29 | $24 | $22 |
| Operating Income | -$34 | -$27 | -$21 | -$20 |
| % Margin | – | -1,347.1% | -930.5% | -985.8% |
| Other Income/Exp. Net | $1 | -$0 | -$0 | $1 |
| Pre-Tax Income | -$33 | -$27 | -$22 | -$19 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$33 | -$27 | -$22 | -$19 |
| % Margin | – | -1,353.6% | -935.2% | -929% |
| EPS | -0.093 | -0.09 | -0.08 | -0.092 |
| % Growth | -2.7% | -12.9% | 12.9% | – |
| EPS Diluted | -0.093 | -0.09 | -0.08 | -0.092 |
| Weighted Avg Shares Out | 353 | 298 | 269 | 205 |
| Weighted Avg Shares Out Dil | 353 | 298 | 269 | 205 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $2 | $1 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$32 | -$27 | -$21 | -$18 |
| % Margin | – | -1,338.8% | -922.1% | -912.9% |